—

Print
Save
Email this link

Share Link

Copy this link, or click below to email it to a friend
Email this link
or copy the link directly:

https://erc.bioscientifica.com/search?access=all&page=7&pageSize=10&q=%22oestrogen%22&sort=relevance
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Search Results

You are looking at 61 - 70 of 430 items for :

"oestrogen" x

Refine by access: All content x

Clear All

Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression

N Sarwar

N Sarwar
Search for other papers by N Sarwar in
Google Scholar
PubMed

J-S Kim

J-S Kim
Search for other papers by J-S Kim in
Google Scholar
PubMed

J Jiang

J Jiang
Search for other papers by J Jiang in
Google Scholar
PubMed

D Peston

D Peston
Search for other papers by D Peston in
Google Scholar
PubMed

H D Sinnett

H D Sinnett
Search for other papers by H D Sinnett in
Google Scholar
PubMed

P Madden

P Madden
Search for other papers by P Madden in
Google Scholar
PubMed

J M Gee

J M Gee
Search for other papers by J M Gee in
Google Scholar
PubMed

R I Nicholson

R I Nicholson
Search for other papers by R I Nicholson in
Google Scholar
PubMed

A E Lykkesfeldt

A E Lykkesfeldt
Search for other papers by A E Lykkesfeldt in
Google Scholar
PubMed

S Shousha

S Shousha
Search for other papers by S Shousha in
Google Scholar
PubMed

R C Coombes

R C Coombes
Search for other papers by R C Coombes in
Google Scholar
PubMed

, and

S Ali

S Ali
Search for other papers by S Ali in
Google Scholar
PubMed

Introduction It is now clear that oestrogens play a central role in promoting breast cancer development and progression ( Ali & Coombes 2002 ). In this respect, oestrogen action is mediated through the oestrogen receptors ERα and ERβ

Article Type:: Research Article

DOI:: https://doi.org/10.1677/erc.1.01123

Volume/Issue:: Volume 13: Issue 3

Free access

Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience

W R Miller

W R Miller
Search for other papers by W R Miller in
Google Scholar
PubMed

T J Anderson

T J Anderson
Search for other papers by T J Anderson in
Google Scholar
PubMed

S White

S White
Search for other papers by S White in
Google Scholar
PubMed

D Evans

D Evans
Search for other papers by D Evans in
Google Scholar
PubMed

A Krause

A Krause
Search for other papers by A Krause in
Google Scholar
PubMed

, and

J M Dixon

J M Dixon
Search for other papers by J M Dixon in
Google Scholar
PubMed

pathological and molecular changes associated with therapy. Response to endocrine therapy Initially, 89 patients were recruited for treatment irrespective of oestrogen receptor (ER) status. However, only 1 of 27 ER-poor tumours (defined as

Article Type:: Research Article

DOI:: https://doi.org/10.1677/erc.1.00995

Volume/Issue:: Volume 12: Issue Supplement_1

Free access

The impact of 27-hydroxycholesterol on endometrial cancer proliferation

Douglas A Gibson

Douglas A Gibson Medical Research Council Centre for Inflammation Research, The University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK

Search for other papers by Douglas A Gibson in
Google Scholar
PubMed

Frances Collins

Frances Collins Medical Research Council Centre for Inflammation Research, The University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK

Search for other papers by Frances Collins in
Google Scholar
PubMed

Fiona L Cousins

Fiona L Cousins Medical Research Council Centre for Inflammation Research, The University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK

Search for other papers by Fiona L Cousins in
Google Scholar
PubMed

Arantza Esnal Zufiaurre

Arantza Esnal Zufiaurre Medical Research Council Centre for Inflammation Research, The University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK

Search for other papers by Arantza Esnal Zufiaurre in
Google Scholar
PubMed

, and

Philippa T K Saunders

Philippa T K Saunders Medical Research Council Centre for Inflammation Research, The University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK

Search for other papers by Philippa T K Saunders in
Google Scholar
PubMed

agonists on the endometrium or endometrial malignancies is not known. In addition to activating LXRs, 27HC can also bind oestrogen receptors (ER) ( Umetani et al . 2007 ) and acts as an endogenous selective oestrogen receptor modulator (SERM) ( DuSell

Article Type:: Research Article

DOI:: https://doi.org/10.1530/ERC-17-0449

Volume/Issue:: Volume 25: Issue 4

Open access

Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study

S C J P Gielen

S C J P Gielen
Search for other papers by S C J P Gielen in
Google Scholar
PubMed

L C M Kühne

L C M Kühne
Search for other papers by L C M Kühne in
Google Scholar
PubMed

P C Ewing

P C Ewing
Search for other papers by P C Ewing in
Google Scholar
PubMed

L J Blok

L J Blok
Search for other papers by L J Blok in
Google Scholar
PubMed

, and

C W Burger

C W Burger
Search for other papers by C W Burger in
Google Scholar
PubMed

Introduction Tamoxifen is the first-choice adjuvant treatment for primary oestrogen receptor-positive (ER+) breast cancer in postmenopausal women. It has been shown that survival rates in tamoxifen-treated women are improved as much

Article Type:: Research Article

DOI:: https://doi.org/10.1677/erc.1.01046

Volume/Issue:: Volume 12: Issue 4

Free access

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer

Anastasia Alataki

Anastasia Alataki Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital and The Institute of Cancer Research, London, UK
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK

Search for other papers by Anastasia Alataki in
Google Scholar
PubMed

and

Mitch Dowsett

Mitch Dowsett Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital and The Institute of Cancer Research, London, UK
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK

Search for other papers by Mitch Dowsett in
Google Scholar
PubMed

Introduction Breast cancer development and progression are significantly affected by signalling pathways involving oestrogen receptor (ER) and growth factor receptors ( Arpino et al. 2008 ). Over 80% of all breast cancer cases are deemed ER

Article Type:: Review Article

DOI:: https://doi.org/10.1530/ERC-21-0293

Volume/Issue:: Volume 29: Issue 8

Open access

Splicing dysregulation as a driver of breast cancer

Abigail Read

Abigail Read The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
Division of Molecular Pathology, The Institute of Cancer Research, London, UK

Search for other papers by Abigail Read in
Google Scholar
PubMed

and

Rachael Natrajan

Rachael Natrajan The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
Division of Molecular Pathology, The Institute of Cancer Research, London, UK

Search for other papers by Rachael Natrajan in
Google Scholar
PubMed

examples of common driver oncogenes and tumour suppressor genes that can be aberrantly spliced in breast cancer. AS has also been shown to regulate protein diversity of the oestrogen receptor itself. In particular, previous studies have shown the ERαΔ5

Article Type:: Review Article

DOI:: https://doi.org/10.1530/ERC-18-0068

Volume/Issue:: Volume 25: Issue 9

Open access

Bringing androgens up a NOTCH in breast cancer

Gerard A Tarulli

Gerard A Tarulli Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) Faculty of Health Sciences, School of Medicine, The University of Adelaide, Adelaide, South Australia 5005, Australia

Search for other papers by Gerard A Tarulli in
Google Scholar
PubMed

Lisa M Butler

Lisa M Butler Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) Faculty of Health Sciences, School of Medicine, The University of Adelaide, Adelaide, South Australia 5005, Australia

Search for other papers by Lisa M Butler in
Google Scholar
PubMed

Wayne D Tilley

Wayne D Tilley Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) Faculty of Health Sciences, School of Medicine, The University of Adelaide, Adelaide, South Australia 5005, Australia

Search for other papers by Wayne D Tilley in
Google Scholar
PubMed

, and

Theresa E Hickey

Theresa E Hickey Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) Faculty of Health Sciences, School of Medicine, The University of Adelaide, Adelaide, South Australia 5005, Australia

Search for other papers by Theresa E Hickey in
Google Scholar
PubMed

Introduction Development of the adult mammary gland and its function are dependent upon oestrogen and progesterone acting via the oestrogen receptor alpha (ERa (ESR1)) and progesterone receptor (PR (PGR)) respectively. During reproductive cycles

Article Type:: Research Article

DOI:: https://doi.org/10.1530/ERC-14-0248

Volume/Issue:: Volume 21: Issue 4

Free access

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

S C Drury

S C Drury Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK
Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by S C Drury in
Google Scholar
PubMed

S Detre

S Detre Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by S Detre in
Google Scholar
PubMed

A Leary

A Leary Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by A Leary in
Google Scholar
PubMed

J Salter

J Salter Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK
Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by J Salter in
Google Scholar
PubMed

J Reis-Filho

J Reis-Filho Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by J Reis-Filho in
Google Scholar
PubMed

V Barbashina

V Barbashina Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by V Barbashina in
Google Scholar
PubMed

C Marchio

C Marchio Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by C Marchio in
Google Scholar
PubMed

E Lopez-Knowles

E Lopez-Knowles Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by E Lopez-Knowles in
Google Scholar
PubMed

Z Ghazoui

Z Ghazoui Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by Z Ghazoui in
Google Scholar
PubMed

K Habben

K Habben Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by K Habben in
Google Scholar
PubMed

S Arbogast

S Arbogast Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by S Arbogast in
Google Scholar
PubMed

S Johnston

S Johnston Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by S Johnston in
Google Scholar
PubMed

, and

M Dowsett

M Dowsett Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK
Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK

Search for other papers by M Dowsett in
Google Scholar
PubMed

Introduction Until recently, tamoxifen has been the gold standard endocrine treatment for oestrogen receptor-positive (ER+) breast cancer and despite the advent of aromatase inhibitors, it continues to be an important therapeutic option. Tamoxifen

Article Type:: Research Article

DOI:: https://doi.org/10.1530/ERC-10-0046

Volume/Issue:: Volume 18: Issue 5

Free access

Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment

Nicoletta Biglia

Nicoletta Biglia Academic Department of Gynaecological Oncology, Mauriziano Umberto I° Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, University of Turin, Largo Turati 62, 10129 Turin, Italy

Search for other papers by Nicoletta Biglia in
Google Scholar
PubMed

Luca Mariani

Luca Mariani Academic Department of Gynaecological Oncology, Mauriziano Umberto I° Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, University of Turin, Largo Turati 62, 10129 Turin, Italy

Search for other papers by Luca Mariani in
Google Scholar
PubMed

Luca Sgro

Luca Sgro Academic Department of Gynaecological Oncology, Mauriziano Umberto I° Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, University of Turin, Largo Turati 62, 10129 Turin, Italy

Search for other papers by Luca Sgro in
Google Scholar
PubMed

Paola Mininanni

Paola Mininanni Academic Department of Gynaecological Oncology, Mauriziano Umberto I° Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, University of Turin, Largo Turati 62, 10129 Turin, Italy

Search for other papers by Paola Mininanni in
Google Scholar
PubMed

Giulia Moggio

Giulia Moggio Academic Department of Gynaecological Oncology, Mauriziano Umberto I° Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, University of Turin, Largo Turati 62, 10129 Turin, Italy

Search for other papers by Giulia Moggio in
Google Scholar
PubMed

, and

Piero Sismondi

Piero Sismondi Academic Department of Gynaecological Oncology, Mauriziano Umberto I° Hospital of Turin and Institute for Cancer Research and Treatment of Candiolo, University of Turin, Largo Turati 62, 10129 Turin, Italy

Search for other papers by Piero Sismondi in
Google Scholar
PubMed

cancer risk of oestrogen plus progestin associations as compared with oestrogen alone (ERT; Colditz et al. 1995 , Persson et al. 1996 , Colditz & Rosner 1998 , Magnusson et al. 2000 , Ross et al. 2000 , Schairer et al. 2000 , Rossouw et